[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 22 of about 22
1. Takagi S, Gohji K, Iwamoto Y, Masuda H, Segawa N, Kiura H, Ueda H, Katsuoka Y: [Ureter cancer of complete double renal pelvis and ureter: a case report]. Hinyokika Kiyo; 2002 Dec;48(12):761-4
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Ureter cancer of complete double renal pelvis and ureter: a case report].
  • Intravenous pyelography, computerized tomography and magnetic resonance imaging revealed ureteral tumors of the complete left double renal pelvis and the ureter.
  • An endoscopic examination disclosed a papillary tumor from the left ureteral orifice of the lower pole of the kidney.
  • A transurethral resection of the tumor was done, and the pathological features revealed transitional cell carcinoma (PTa, grade 2).
  • A left nephroureterectomy and a partial cystectomy were also carried out; macroscopic examinations showed a non-papillary tumor on the middle portion of the left ureter originating from the upper pole of the kidney.
  • Microscopic examinations revealed transitional cell carcinoma (PT3, grade 3, PL1, PV1).
  • Adjuvant chemotherapy (M-VAC) was administered but discontinued because of severe side effects.
  • Dispite recurrence with retro-peritoneal lymph node metastasis, the patient is alive and again undergoing M-VAC chemotherapy 22 months after the initial surgery.
  • However, the evaluation of the chemotherapy was "no change".
  • [MeSH-major] Carcinoma, Transitional Cell / surgery. Kidney Neoplasms / surgery. Kidney Pelvis / abnormalities. Neoplasms, Multiple Primary. Ureter / abnormalities. Ureteral Neoplasms / surgery
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Humans. Lymphatic Metastasis. Male. Neoplasm Recurrence, Local. Urinary Bladder Neoplasms / pathology. Urinary Bladder Neoplasms / surgery. Urologic Surgical Procedures

  • Genetic Alliance. consumer health - Kidney cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12613013.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 16
  •  go-up   go-down


2. Chen WJ, Kuo JY, Chen KK, Lin AT, Chang YH, Chang LS: Primary urothelial carcinoma of the ureter: 11-year experience in Taipei Veterans General Hospital. J Chin Med Assoc; 2005 Nov;68(11):522-30

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary urothelial carcinoma of the ureter: 11-year experience in Taipei Veterans General Hospital.
  • BACKGROUND: Urothelial carcinoma of the upper urinary tract is relatively rare, occurring in 5% of all urothelial tumors.
  • Ureteral urothelial carcinoma is even less common than that of the renal pelvis, accounting for about 25% of all upper urinary tract tumors.
  • The aim of this study was to evaluate the clinical behavior, survival, recurrence and prognostic information of primary ureteral urothelial carcinoma from our 11 years of experience at the Taipei Veterans General Hospital.
  • METHODS: We retrospectively reviewed 111 patients with ureteral urothelial carcinoma who had been treated in our hospital between January 1993 and December 2003.
  • Tumor staging was according to the 2002 AJCC TNM classification and stage groupings.
  • Nephroureterectomy with bladder cuff excision was performed in 78 patients, 12 patients received segmental resection of the ureter, 4 received ureteroscopic laser coagulation, and 17 underwent chemotherapy or radiotherapy or both.
  • Disease recurrence in the nephroureterectomy group occurred in 36 patients (46.2%), with 17 (21.8%) at the urinary bladder, 2 (2.6%) at the retroperitoneum, 1 (1.3%) at the contralateral ureter, 6 (7.7%) with distant metastases to the lung, bone, distant lymph nodes or liver, and 10 (12.8%) at multiple sites.
  • The 5-year cancer-specific survival rate was 100% for pTa/is, 95.2% for pT1, 69.4% for pT2, and 43.8% for pT3.
  • All 3 pT4 cases died of cancer in a median of 12 months.
  • Significant prognostic factors for cancer-specific survival by univariate analysis were pT (p = 0.00001), stage (p = 0.00001), type of treatment (p = 0.00001) and grade (p = 0.0001).
  • On multivariate analysis, only stage (p = 0.0001) and grade (p = 0.014) were significant for cancer-specific and overall survival.
  • Tumor stage and grade are the only significant prognostic factors for both cancer-specific and overall survival.
  • [MeSH-major] Ureteral Neoplasms / mortality
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16323396.001).
  • [ISSN] 1726-4901
  • [Journal-full-title] Journal of the Chinese Medical Association : JCMA
  • [ISO-abbreviation] J Chin Med Assoc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down


3. Giannarini G, Schumacher MC, Thalmann GN, Bitton A, Fleischmann A, Studer UE: Elective management of transitional cell carcinoma of the distal ureter: can kidney-sparing surgery be advised? BJU Int; 2007 Aug;100(2):264-8
Genetic Alliance. consumer health - Transitional cell carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elective management of transitional cell carcinoma of the distal ureter: can kidney-sparing surgery be advised?
  • OBJECTIVE: To determine the long-term oncological outcome of patients with primary transitional cell carcinoma (TCC) of the distal ureter electively treated with either kidney-sparing surgery (KSS) or radical nephroureterectomy (RNU) in a retrospective, non-randomized, single-centre study.
  • PATIENTS AND METHODS: Of 43 consecutive patients with a primary solitary distal ureter TCC, 19 had KSS, consisting of distal ureter resection with bladder cuff excision and ureter reimplantation, and 24 had RNU with bladder cuff excision.
  • Five of the 19 patients treated by KSS and six of the 24 treated by RNU died from metastatic disease despite chemotherapy.
  • Recurrence-free, cancer-specific and overall survival were comparable in the two groups.
  • CONCLUSION: Treatment by distal ureteric resection is feasible in patients with primary TCC of the distal ureter.
  • Furthermore, kidney preservation is advantageous if adjuvant or salvage chemotherapy is required.
  • [MeSH-major] Carcinoma, Transitional Cell / surgery. Kidney / surgery. Nephrectomy / methods. Ureter / surgery. Ureteral Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Feasibility Studies. Follow-Up Studies. Humans. Hydronephrosis / complications. Hydronephrosis / pathology. Hydronephrosis / surgery. Middle Aged. Neoplasm Recurrence, Local. Retrospective Studies. Treatment Outcome. Urinary Bladder Neoplasms / complications. Urinary Bladder Neoplasms / pathology. Urinary Bladder Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17532855.001).
  • [ISSN] 1464-4096
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


Advertisement
4. Favaretto RL, Shariat SF, Chade DC, Godoy G, Adamy A, Kaag M, Bochner BH, Coleman J, Dalbagni G: The effect of tumor location on prognosis in patients treated with radical nephroureterectomy at Memorial Sloan-Kettering Cancer Center. Eur Urol; 2010 Oct;58(4):574-80
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effect of tumor location on prognosis in patients treated with radical nephroureterectomy at Memorial Sloan-Kettering Cancer Center.
  • BACKGROUND: The prognostic impact of primary tumor location on outcomes for patients with upper-tract urothelial carcinoma (UTUC) is still contentious.
  • OBJECTIVE: To test the association between tumor location and disease recurrence and cancer-specific survival (CSS) in patients treated with radical nephroureterectomy (RNU) for UTUC.
  • Patients who had previous radical cystectomy, preoperative chemotherapy, previous contralateral UTUC, or metastatic disease at presentation were excluded.
  • Tumor location was categorized as renal pelvis or ureter based on the location of the dominant tumor.
  • RESULTS AND LIMITATIONS: Median follow-up for survivors was 48 mo.
  • Tumor location was not an independent predictor for recurrence (hazard ratio: 1.19; p=0.3), and there was no difference in the probability of disease recurrence between ureteral and renal pelvic tumors (p=0.18).
  • On survival analysis, we also found no differences between ureteral and renal pelvic tumors on probability of CSS (p=0.2).
  • CONCLUSIONS: Our study did not show any differences in recurrence and CSS rates between patients with ureteral and renal pelvic tumors treated with RNU.
  • [MeSH-major] Carcinoma, Transitional Cell / surgery. Kidney Neoplasms / surgery. Kidney Pelvis. Nephrectomy. Ureter / surgery. Ureteral Neoplasms / surgery
  • [MeSH-minor] Aged. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Prognosis. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 European Association of Urology. Published by Elsevier B.V. All rights reserved.
  • [Cites] J Clin Oncol. 2009 Feb 1;27(4):612-8 [19075275.001]
  • [Cites] Eur Urol. 2008 Apr;53(4):794-802 [18207313.001]
  • [Cites] J Urol. 2009 Nov;182(5):2177-81 [19758662.001]
  • [Cites] Eur Urol. 2005 Sep;48(3):438-44 [16115524.001]
  • [Cites] Am J Surg Pathol. 1998 Dec;22(12):1435-48 [9850170.001]
  • [Cites] Urology. 1998 Oct;52(4):594-601 [9763077.001]
  • [Cites] Urology. 1997 Sep;50(3):321-9 [9301692.001]
  • [Cites] Cancer. 1988 Nov 1;62(9):2016-20 [3167813.001]
  • [Cites] Cancer. 2009 Mar 15;115(6):1224-33 [19156917.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] J Urol. 2009 Sep;182(3):894-9 [19616243.001]
  • [Cites] Eur Urol. 2010 Jun;57(6):1072-9 [19619934.001]
  • [Cites] J Urol. 2000 Nov;164(5):1523-5 [11025695.001]
  • [Cites] J Urol. 2004 Feb;171(2 Pt 1):621-5 [14713773.001]
  • [CommentIn] Eur Urol. 2011 Apr;59(4):e23 [21255908.001]
  • [CommentIn] Eur Urol. 2011 Jan;59(1):e2 [20980096.001]
  • [CommentIn] J Urol. 2011 Feb;185(2):463 [22088622.001]
  • (PMID = 20637540.001).
  • [ISSN] 1873-7560
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / T32 CA082088
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Other-IDs] NLM/ NIHMS628548; NLM/ PMC4174409
  •  go-up   go-down


5. Brown GA, Busby JE, Wood CG, Pisters LL, Dinney CP, Swanson DA, Grossman HB, Pettaway CA, Munsell MF, Kamat AM, Matin SF: Nephroureterectomy for treating upper urinary tract transitional cell carcinoma: Time to change the treatment paradigm? BJU Int; 2006 Dec;98(6):1176-80
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nephroureterectomy for treating upper urinary tract transitional cell carcinoma: Time to change the treatment paradigm?
  • OBJECTIVE: To evaluate factors associated with disease recurrence and survival in patients undergoing nephroureterectomy for upper urinary tract transitional cell carcinoma (UUT-TCC) in one centre over an 18-year period.
  • PATIENTS AND METHODS: The records of patients who had a nephroureterectomy for UUT-TCC at our institution from 1986 to 2004 were reviewed for clinical, pathological and treatment period data.
  • In 44 patients, the disease recurred outside the bladder; 15 (8.2%) had local recurrence, 20 (10.9%) distant metastasis, and nine (4.9%) both local and distant recurrence.
  • The evaluation of treatment outcome during three periods of the study showed no significant effect on DSS.
  • Patients with high-stage and high-grade disease continue to fare poorly, suggesting a need for changing the treatment protocol.
  • Judiciously applying a multimodal approach to the management of high-risk patients by incorporating neoadjuvant chemotherapy and surgical resection might provide, for the first time, the opportunity to improve patient outcome.
  • [MeSH-major] Carcinoma, Transitional Cell / surgery. Kidney Neoplasms / surgery. Nephrectomy / methods. Ureteral Neoplasms / surgery
  • [MeSH-minor] Aged. Cohort Studies. Disease-Free Survival. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoadjuvant Therapy / methods. Neoplasm Recurrence, Local / surgery. Neoplasm Staging / methods. Prognosis. Treatment Outcome. Ureter / surgery

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur Urol. 2007 Apr;51(4):1141-2 [17415912.001]
  • (PMID = 17125474.001).
  • [ISSN] 1464-4096
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA91846; United States / NCI NIH HHS / CA / T32 CA079449-06
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


6. Ito K, Wong L, Ando H, Hibi K, Hidemura K, Yamazaki T, Kasai Y, Akiyama S, Nakao A, Ikeda S: Newly developed drug delivery system in cancer chemotherapy using direct electric current. ASAIO J; 2001 Jul-Aug;47(4):338-41
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Newly developed drug delivery system in cancer chemotherapy using direct electric current.
  • To improve the antitumor effect of chemotherapy on a target organ, we experimentally investigated pharmacokinetic alteration of methotrexate (MTX) induced by an electric current in rats to ascertain whether the local concentration of MTX could be enhanced while reducing the concentration in blood.
  • The MTX concentration in urine (excreted from each ureter) and serum was measured by fluorescence polarization immunoassay.
  • Electric therapy using a slight direct current could gather anionized MTX to the cathode, while reducing MTX concentration in the serum of experimental rats.
  • [MeSH-major] Drug Delivery Systems / methods. Electric Stimulation Therapy / methods. Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11482482.001).
  • [ISSN] 1058-2916
  • [Journal-full-title] ASAIO journal (American Society for Artificial Internal Organs : 1992)
  • [ISO-abbreviation] ASAIO J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


7. Wu WJ, Ke HL, Yang YH, Li CC, Chou YH, Huang CH: Should patients with primary upper urinary tract cancer receive prophylactic intravesical chemotherapy after nephroureterectomy? J Urol; 2010 Jan;183(1):56-61
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Should patients with primary upper urinary tract cancer receive prophylactic intravesical chemotherapy after nephroureterectomy?
  • PURPOSE: We assessed the efficacy of prophylactic intravesical chemotherapy for primary upper urinary tract urothelial cancer after nephroureterectomy during long-term followup.
  • MATERIALS AND METHODS: From January 1985 to June 2007, 196 patients with primary upper urinary tract urothelial cancer were included in this study.
  • We compared the bladder tumor recurrence rate, number of recurrence episodes, time to first bladder tumor recurrence, tumor type, percent of patients with cystectomy and percent who died of urothelial cancer, and the recurrence-free survival rate.
  • There were no significant differences in recurrence type, mean number of bladder tumor recurrences, percent of patients with cystectomy and the cancer specific survival rate.
  • Mean time to first bladder tumor recurrence was longer in groups 1 and 2.
  • CONCLUSIONS: Intravesical instillation of epirubicin or mitomycin C appears to be well tolerated and effective for preventing bladder recurrence and prolonging time to first bladder recurrence.
  • Patients should receive prophylactic intravesical chemotherapy after nephroureterectomy.
  • [MeSH-major] Antibiotics, Antineoplastic / administration & dosage. Carcinoma, Transitional Cell / prevention & control. Carcinoma, Transitional Cell / surgery. Epirubicin / administration & dosage. Kidney Neoplasms / prevention & control. Kidney Neoplasms / surgery. Mitomycin / administration & dosage. Neoplasm Recurrence, Local / prevention & control. Nephrectomy. Ureter / surgery. Ureteral Neoplasms / prevention & control. Ureteral Neoplasms / surgery
  • [MeSH-minor] Administration, Intravesical. Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Postoperative Care. Retrospective Studies. Time Factors. Young Adult


8. Kirkali Z, Tuzel E: Transitional cell carcinoma of the ureter and renal pelvis. Crit Rev Oncol Hematol; 2003 Aug;47(2):155-69
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transitional cell carcinoma of the ureter and renal pelvis.
  • Transitional cell carcinoma (TCC) of ureter and renal pelvis is relatively uncommon.
  • Approximately 20-50% of patients with upper urinary tract (UUT) TCC have bladder cancer at some point on their course, whereas the incidence of UUT TCC after primary bladder cancer is 0.7-4%.
  • Nephroureterectomy with bladder cuff excision has been the mainstay of treatment.
  • Local resection may be appropriate for distal ureteral lesions especially when the disease is low grade and stage.
  • Adjuvant topical therapies appear to be safe but confirmation of any benefits awaits the results of further large studies.
  • More recently, laparoscopic techniques have become a viable alternative to open surgery, but long term cancer control data are lacking.
  • Adjuvant radiotherapy is ineffective, and systemic chemotherapy results in a low complete response rate for patients with metastases.
  • [MeSH-major] Carcinoma, Transitional Cell. Kidney Neoplasms. Ureteral Neoplasms
  • [MeSH-minor] Combined Modality Therapy. Humans. Kidney Pelvis / pathology. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / etiology. Urinary Bladder Neoplasms / therapy

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12900009.001).
  • [ISSN] 1040-8428
  • [Journal-full-title] Critical reviews in oncology/hematology
  • [ISO-abbreviation] Crit. Rev. Oncol. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Number-of-references] 146
  •  go-up   go-down


9. Haddock MG, Gunderson LL, Nelson H, Cha SS, Devine RM, Dozois RR, Wolff BG: Intraoperative irradiation for locally recurrent colorectal cancer in previously irradiated patients. Int J Radiat Oncol Biol Phys; 2001 Apr 1;49(5):1267-74
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraoperative irradiation for locally recurrent colorectal cancer in previously irradiated patients.
  • PURPOSE: Information in the literature regarding salvage treatment for patients with locally recurrent colorectal cancer who have previously been treated with high or moderate dose external beam irradiation (EBRT) is scarce.
  • A retrospective review was therefore performed in our institution to determine disease control, survival, and tolerance in patients treated aggressively with surgical resection and intraoperative electron irradiation (IOERT) +/- additional EBRT and chemotherapy.
  • METHODS AND MATERIALS: From 1981 through 1994, 51 previously irradiated patients with recurrent locally advanced colorectal cancer without evidence of distant metastatic disease were treated at Mayo Clinic Rochester with surgical resection and IOERT +/- additional EBRT.
  • The median IOERT dose was 20 Gy (range, 10--30 Gy).
  • Thirty-seven patients received additional EBRT either pre- or postoperatively with doses ranging from 5 to 50.4 Gy (median 25.2 Gy).
  • Three patients received additional cycles of 5-fluorouracil +/- leucovorin as maintenance chemotherapy.
  • Local control at 2 years has been maintained in 60% of patients.
  • There is a trend toward improved local control in patients who received > or =30 Gy EBRT in addition to IOERT as compared to those who received no EBRT or <30 Gy with 2-yr local control rates of 81% vs. 54%.
  • Distant metastatic disease has developed in 25 patients, and the actuarial rate of distant progression at 2 and 4 years is 56% and 76%, respectively.
  • Peripheral neuropathy was the main IOERT-related toxicity; 16 (32%) patients developed neuropathies (7 mild, 5 moderate, 4 severe).
  • Ureteral narrowing or obstruction occurred in seven patients.
  • All but one patient with neuropathy or ureter fibrosis received IOERT doses > or =20 Gy.
  • CONCLUSION: Long-term local control can be obtained in a substantial proportion of patients with aggressive combined modality therapy, but long-term survival is poor due to the high rate of distant metastasis.
  • Re-irradiation with EBRT in addition to IOERT appears to improve local control.
  • Strategies to improve survival in these poor-risk patients may include the more routine use of conventional systemic chemotherapy or the addition of novel systemic therapies.
  • [MeSH-major] Colonic Neoplasms / radiotherapy. Neoplasm Recurrence, Local / radiotherapy. Rectal Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Analysis of Variance. Antimetabolites, Antineoplastic / therapeutic use. Female. Fluorouracil / therapeutic use. Follow-Up Studies. Humans. Leucovorin / therapeutic use. Male. Middle Aged. Radiotherapy Dosage. Retrospective Studies. Salvage Therapy. Survival Analysis

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11286833.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


10. Eloubeidi MA, Varadarajulu S, El-Galley R, Bueschen AJ, Eltoum I: EUS-guided FNA for the diagnosis of recurrent bladder cancer through the ileal conduit: a novel approach. Gastrointest Endosc; 2006 Sep;64(3):450-3
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EUS-guided FNA for the diagnosis of recurrent bladder cancer through the ileal conduit: a novel approach.
  • BACKGROUND: Diagnosing local recurrence of tumor after cystectomy and ileal conduit construction for urinary bladder cancer remains a diagnostic challenge.
  • Also, distinction of benign stricture from recurrent tumor at the site of ureteral anastomosis in the ileal conduit is difficult.
  • OBJECTIVE: A new method is described for performing EUS-guided FNA through the ileal conduit in patients suspected of having local tumor recurrence after complete cystectomy for bladder cancer.
  • PATIENTS: Three patients who had undergone total cystectomy and ileal conduit construction for bladder cancer underwent EUS-guided FNA through the ileal conduit for evaluation of suspected tumor recurrence at the site of anastomosis of the distal ureter and the ileal conduit.
  • A diagnosis of recurrent transitional cell cancer was made in 2 patients and anastomotic stricture was found in 1 patient.
  • Both patients with tumor recurrence received palliative chemotherapy, and the patient with an anastomotic stricture was managed by placement of a nephrostomy stent.
  • CONCLUSIONS: EUS-guided FNA through the ileal conduit is technically feasible, safe, and establishes diagnosis in patients suspected of tumor recurrence after complete cystectomy for bladder cancer.
  • [MeSH-major] Biopsy, Fine-Needle / methods. Endosonography / methods. Neoplasm Recurrence, Local / ultrasonography. Urinary Bladder Neoplasms / ultrasonography

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16923503.001).
  • [ISSN] 0016-5107
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Miao M, Kong CZ, Li ZH, Liu XK, Sun ZX: [The clinical study for reducing bladder cancer recurrence after surgical treatment for renal pelvic carcinoma]. Zhonghua Wai Ke Za Zhi; 2009 May 15;47(10):728-30
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The clinical study for reducing bladder cancer recurrence after surgical treatment for renal pelvic carcinoma].
  • OBJECTIVE: To investigate the clinical methods for reducing bladder cancer recurrence after surgical treatment for renal pelvic carcinoma.
  • METHODS: From October 1997 to December 2007, the data of 227 patients undergoing total nephroureterectomy for clinically localized transitional cell carcinoma of the renal pelvis with follow-up results were analyzed retrospectively, including 126 cases of male and 101 cases of female, and the age was 34 to 78 years old.
  • There were 2 kinds of technique used in the dissection of bladder wall circumferentially around the ureteral orifice.
  • Technique A was dissection along the ipsilateral ureter to the bladder wall.
  • Technique B was dissection along the vas deferens to the bladder wall circumferentially around the ipsilateral ureteral orifice and division of the lateral vesical ligament to reach the seminal vesicle.
  • Prophylactic intravesical chemotherapy included 3 method.
  • Method 1 was intraoperative intravesical chemotherapy and then administrated once a week, 10 times in total.
  • Method 2 was intraoperative intravesical chemotherapy and then administrated once a week from the 4(th) week after operation, 10 times in total.
  • Method 3 was intravesical chemotherapy was given once a week from the 4(th) week after operation, 10 times in total.
  • The time of follow-up was 1 to 10 years with regular cystoscopy.
  • Chi-square test and Logistic regression were used to analyzed the recurrence rate of bladder cancer.
  • RESULTS: Recurrence rate of bladder cancer was 27.8% (63/227).
  • The recurrence rates of bladder cancer in patients using technique A and B were 18.0% (7/39) and 12.5% (3/24), respectively (P < 0.05).
  • The postoperative recurrence rates of bladder cancer in patients using 3 kinds of intravesical chemotherapy regimen were 17.9% (11/67), 20.8% (10/48) and 33.3% (17/51), respectively.
  • There was significant difference between the recurrence rates of patients using method 1 and method 3 intravesical chemotherapy (P < 0.05).
  • CONCLUSION: Complete removal of the bladder mucosa circumferentially around the ureteral orifice, administration of the intraoperative intravesical chemotherapy instillation and instillation once a week may be a useful approach to reduce the recurrence of bladder cancer after operation for renal pelvic carcinoma.
  • [MeSH-major] Carcinoma, Renal Cell / surgery. Kidney Neoplasms / surgery. Kidney Pelvis. Urinary Bladder Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. Chemotherapy, Cancer, Regional Perfusion. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / prevention & control. Postoperative Care. Retrospective Studies

  • Genetic Alliance. consumer health - Kidney cancer.
  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19615202.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


12. Dowdy SC, Mariani A, Cliby WA, Haddock MG, Petersen IA, Sim FH, Podratz KC: Radical pelvic resection and intraoperative radiation therapy for recurrent endometrial cancer: technique and analysis of outcomes. Gynecol Oncol; 2006 May;101(2):280-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radical pelvic resection and intraoperative radiation therapy for recurrent endometrial cancer: technique and analysis of outcomes.
  • OBJECTIVE: To describe the technique and assess outcomes and morbidity following radical resection combined with intraoperative electron radiation therapy (IOERT) in patients with recurrent endometrial cancer.
  • METHODS: From 1986 to 2002, 25 patients received treatment including radical resection and IOERT for recurrent endometrioid, endometrial cancer.
  • RESULTS: Treatment prior to referral included radiation in 56% and either a secondary surgery or chemotherapy in 48%.
  • Radical procedures performed at the time of IOERT included resection of the pelvic sidewall en bloc with the obturator nerve, external iliac vein, psoas, iliacus, or obturator internus muscles, ureter, or boney ileum.
  • Proportional hazards modeling showed concurrent EBRT, tumor size after resection, grade, and age to be associated with improved survival.
  • The most common complications were peripheral neuropathy, functional ureteral obstruction, and fistula formation.
  • CONCLUSIONS: With an aggressive treatment approach including radical resection combined with IOERT, long-term survival is possible in a significant number of patients with localized recurrent endometrial cancer.
  • [MeSH-major] Carcinoma, Endometrioid / radiotherapy. Carcinoma, Endometrioid / surgery. Electrons / therapeutic use. Endometrial Neoplasms / radiotherapy. Endometrial Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Gynecologic Surgical Procedures. Humans. Middle Aged. Neoplasm Recurrence, Local / pathology. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16321431.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Zhang M, Tao R, Zhang C, Shen Z: Lymphovascular invasion and the presence of more than three tumors are associated with poor outcomes of muscle-invasive bladder cancer after bladder-conserving therapies. Urology; 2010 Oct;76(4):902-7
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphovascular invasion and the presence of more than three tumors are associated with poor outcomes of muscle-invasive bladder cancer after bladder-conserving therapies.
  • OBJECTIVES: To identify the predictive factors for survival and recurrence of patients with muscle-invasive bladder cancer (MIBC) (urothelial carcinoma) after bladder-conserving therapies and to determine the efficacy of partial cystectomy plus chemotherapy and radiotherapy in the treatment of MIBC.
  • Subjects who had stage pT3-4 disease received adjuvant chemotherapy and radiotherapy.
  • RESULTS: At median follow-up of 31.5 months (range 6-66 months), 46% patients experienced superficial local recurrence and 14% developed muscle-invasive local recurrence.
  • At the end of follow-up, 24 patients died of bladder cancer, and 71 patients (71%) survived with intact bladders.
  • The 5-year cancer-specific survival (CSS) rate was 68%.
  • By multivariate analysis, the presence of more than 3 tumors (P = .002, RR 2.718, 95% CI 1.455-5.079) and nonpapillary growth patterns (P = .005, RR 4.537, 95% CI 1.573-13.081) were predictive factors for local cancer recurrence; the presence of more than 3 tumors (P = .002, RR 4.109, 95% CI 1.676-10.072), lymphovascular invasion (P = .001, RR 6.098, 95% CI 2.038-18.246), and partial cystectomy plus ureteral reimplantation (PC plus UR) (P = .011, RR 0.129, 95% CI .027-0.627) were significantly associated with 5-year CSS, and PC plus UR promoted survival.
  • CONCLUSIONS: PC plus chemotherapy and radiotherapy is a rational alternative to radical cystectomy for the treatment of MIBC.
  • Lymphovascular invasion and the presence of more than 3 tumors predict poor outcomes in MIBC after bladder-sparing therapy.
  • [MeSH-major] Blood Vessels / pathology. Carcinoma, Transitional Cell / secondary. Lymphatic Metastasis. Neoplasms, Multiple Primary / pathology. Urinary Bladder / surgery. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Lymph Node Excision. Male. Middle Aged. Muscle, Smooth / pathology. Neoplasm Invasiveness. Neoplasm Recurrence, Local / epidemiology. Proportional Hazards Models. Radiotherapy, Adjuvant. Replantation. Treatment Outcome. Ureter / surgery

  • Genetic Alliance. consumer health - Bladder cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20709377.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Rassweiler J, Tsivian A, Kumar AV, Lymberakis C, Schulze M, Seeman O, Frede T: Oncological safety of laparoscopic surgery for urological malignancy: experience with more than 1,000 operations. J Urol; 2003 Jun;169(6):2072-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Although laparoscopy is being increasingly used to treat urological malignancies, there is still concern regarding the induction of local recurrence and port site metastasis.
  • We assessed the oncological safety of laparoscopy with emphasis on incidence of local recurrence and port site metastasis, analyzing the risk factors for such events based on a 10-year experience.
  • A total of 567 procedures were performed in case of histologically proven cancer, whereas 531 represented only staging operations.
  • Eight local recurrences were observed (0.73% overall, 1.41% of histologically proven cases).
  • There were recurrences after nephroureterectomy for transitional cell carcinoma of the ureter in 1 patient, after radical nephrectomy for renal cell carcinoma in 1, growing teratoma after retroperitoneal lymph node dissection in 2, local recurrence of prostate cancer in 3 and after removal of an adrenal metastasis of melanoma in 1.
  • Two port site metastases (0.18% overall, 0.35% of histologically proved cases) occurred, including metastasis of small cell lung carcinoma after adrenalectomy and a residual mass following 2 cycles of chemotherapy after retroperitoneal lymph node dissection.
  • CONCLUSIONS: According to our experience the incidence of local recurrence and the risk of port site metastases is low and seems to be mainly related to the aggressiveness of the tumor and immunosuppression status of the patient, respectively rather than to technical aspects of the laparoscopic approach.
  • [MeSH-minor] Adrenalectomy. Adult. Aged. Aged, 80 and over. Female. Humans. Lymph Node Excision. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Seeding. Nephrectomy. Pelvis. Postoperative Complications. Prostatectomy. Ureter / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12771722.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Querleu D, Dargent D, Ansquer Y, Leblanc E, Narducci F: Extraperitoneal endosurgical aortic and common iliac dissection in the staging of bulky or advanced cervical carcinomas. Cancer; 2000 Apr 15;88(8):1883-91
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The indication for extended lymph node staging was bulky early stage in 33 patients, International Federation of Gynecology and Obstetrics distal Stage IIB or higher in 14 patients, nonbulky early stage with microscopic positive pelvic lymph nodes in 1 patient, and central recurrence in 5 patients.
  • RESULTS: The procedure failed in two patients.
  • An intraoperative complication occurred in one patient, in whom a lateral injury to a fixed and dilated ureter was managed by stenting.
  • A postoperative complication occurred in another patient, in whom a retroperitoneal hematoma causing ileus and compression of the upper ureter was managed conservatively.
  • All patients but one had external radiation therapy tailored according to the aortic lymph node status.
  • Two patients developed radiation enteritis.
  • CONCLUSIONS: This new technique deserves to be used as a tool to identify lymph node positive patients who require extended-field radiation and/or chemotherapy.
  • [MeSH-major] Lymph Node Excision / methods. Minimally Invasive Surgical Procedures / methods. Neoplasm Staging / methods. Uterine Cervical Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aorta. Endoscopy / methods. Female. Humans. Iliac Artery. Lymphatic Metastasis / diagnosis. Middle Aged. Neoplasm Recurrence, Local. Postoperative Complications. Treatment Outcome


16. Thalmann GN, Markwalder R, Walter B, Studer UE: Long-term experience with bacillus Calmette-Guerin therapy of upper urinary tract transitional cell carcinoma in patients not eligible for surgery. J Urol; 2002 Oct;168(4 Pt 1):1381-5
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term experience with bacillus Calmette-Guerin therapy of upper urinary tract transitional cell carcinoma in patients not eligible for surgery.
  • PURPOSE: Carcinoma in situ and urothelial tumors of the upper urinary tract become problematic in cases of bilateral occurrence or solitary kidney.
  • Perfusions with bacillus Calmette-Guerin (BCG) have been reported beneficial, however, only long-term results will determine the validity of this treatment.
  • MATERIALS AND METHODS: We retrospectively evaluated the results of BCG therapy for upper urinary tract disease in 37 patients.
  • All 37 patients had undergone previous surgical treatment for urothelial cancer, had a positive cytology or biopsy for upper urinary tract cancer and were ineligible for radical nephroureterectomy with a bladder cuff.
  • After placement of a 10Fr nephrostomy tube with the patient under local anesthesia 6 weekly perfusions of BCG were administered after radiological documentation of unhindered flow from the renal pelvis to the bladder or urinary diversion.
  • A total of 25 renal units were treated with curative intent for carcinoma in situ and 16 renal units were treated for Ta or higher urothelial tumors in an adjuvant setting after endoscopic resection.
  • In 1 patient BCG inflammation and in 2 others severe septicemia developed after the first perfusion.
  • There was no tumor seeding along the nephrostomy tract in any patient.
  • BCG perfusion therapy did not alter renal function.
  • Of the 37 patients 14 (38%) died of urothelial cancer, 11 of other causes (29%) and 12 (33%) are alive.
  • CONCLUSIONS: BCG perfusion therapy of the upper urinary tract for papillary tumors or carcinoma in situ is a valid treatment option with acceptable side effects for patients not amenable to conventional radical surgical therapy.
  • BCG therapy of upper urinary tract urothelial tumors may prevent patients from requiring dialysis and provides cure in those with carcinoma in situ of the upper urinary tract.
  • In this negatively selected patient population BCG buys time for some but does not provide cure except for carcinoma in situ.
  • [MeSH-major] BCG Vaccine / therapeutic use. Carcinoma in Situ / drug therapy. Carcinoma, Transitional Cell / drug therapy. Kidney Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / surgery. Neoplasm Staging. Nephrectomy. Nephrostomy, Percutaneous. Perfusion. Retrospective Studies. Survival Rate. Ureter / pathology. Ureter / surgery. Ureteral Neoplasms / drug therapy. Ureteral Neoplasms / mortality. Ureteral Neoplasms / pathology. Ureteral Neoplasms / surgery. Urinary Bladder Neoplasms / drug therapy. Urinary Bladder Neoplasms / mortality. Urinary Bladder Neoplasms / pathology. Urinary Bladder Neoplasms / surgery. Urinary Diversion

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12352398.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BCG Vaccine
  •  go-up   go-down


17. Zhang Y, Gu ZY, Tian Z, Yang C, Cai XY: Oral metastasis from primary transitional cell carcinoma of the renal pelvis: report of a case. Int J Oral Maxillofac Surg; 2010 Jul;39(7):737-9
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oral metastasis from primary transitional cell carcinoma of the renal pelvis: report of a case.
  • Transitional cell carcinoma of the renal pelvis is initially a slow growing tumor arising from the transitional epithelium of the mucous membrane of the renal pelvis.
  • Recurrences occur in two forms: superficial bladder cancer and distant metastases.
  • The authors report an unusual case of transitional cell carcinoma of the renal pelvis metastasized to the oral cavity and lung simultaneously in a 74-year-old man, which occurred 1 year after a left nephroureterectomy.
  • The patient underwent six courses of chemotherapy (gemcitabine, oxaliplatin, fluorouracil and nedaplatin), and received radiotherapy for the oral lesion.
  • The symptoms were alleviated, but the tumor recurred in the oral cavity 2 years later.
  • [MeSH-major] Carcinoma, Transitional Cell / secondary. Kidney Neoplasms / pathology. Kidney Pelvis / pathology. Mouth Neoplasms / secondary
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Fatal Outcome. Follow-Up Studies. Humans. Lung Neoplasms / secondary. Male. Neoadjuvant Therapy. Neoplasm Recurrence, Local / pathology. Nephrectomy. Radiotherapy, Adjuvant. Ureter / surgery

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 International Association of Oral and Maxillofacial Surgeons. Published by Elsevier Ltd. All rights reserved.
  • (PMID = 20236801.001).
  • [ISSN] 1399-0020
  • [Journal-full-title] International journal of oral and maxillofacial surgery
  • [ISO-abbreviation] Int J Oral Maxillofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  •  go-up   go-down


18. Bartsch GC, Kuefer R, Gschwend JE, de Petriconi R, Hautmann RE, Volkmer BG: Hydronephrosis as a prognostic marker in bladder cancer in a cystectomy-only series. Eur Urol; 2007 Mar;51(3):690-7; discussion 697-8
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hydronephrosis as a prognostic marker in bladder cancer in a cystectomy-only series.
  • OBJECTIVES: Hydronephrosis in patients with bladder cancer is caused by tumour at the ureteral orifice, secondary ureteral tumours, intramural or extravesical tumour infiltration, or compression of the ureter.
  • This study investigated the prognostic impact of hydronephrosis in bladder cancer.
  • METHODS: A series of 788 patients were treated with radical cystectomy with curative intent for transitional cell carcinoma of the bladder without neoadjuvant/adjuvant radiotherapy/chemotherapy between January 1986 and September 2003.
  • Forty-three (32.3%) of the 133 hydronephrotic patients had a tumour involving the ureteral orifice.
  • CONCLUSIONS: Hydronephrosis at the time of diagnosis of bladder cancer is associated with a high probability of advanced tumours.
  • [MeSH-major] Carcinoma, Transitional Cell / complications. Carcinoma, Transitional Cell / surgery. Cystectomy. Hydronephrosis / etiology. Urinary Bladder Neoplasms / complications. Urinary Bladder Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Prognosis. Survival Rate

  • Genetic Alliance. consumer health - Bladder cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur Urol. 2007 Mar;51(3):591-2 [17174022.001]
  • (PMID = 16904815.001).
  • [ISSN] 0302-2838
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


19. Tadokoro M, Masuda H, Fujii Y, Kobayashi T, Kageyama Y, Kihara K: Late relapse of stage I testicular seminoma metastatic to just a para-ureteropelvic region. Int J Urol; 2004 Nov;11(11):1044-6
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late relapse of stage I testicular seminoma metastatic to just a para-ureteropelvic region.
  • Computed tomography scans of the abdomen showed a bulky tumor around the ureteropelvic region without para-aortic lymph node enlargement, but did not show a clear distinction between a recurrence of the testicular tumor and an invasive ureteral tumor.
  • After the patient underwent two cycles of chemotherapy with cisplatin and etoposide, the tumor mass decreased by approximately 60% and beta-hCG levels returned to normal.
  • We then performed a resection of the residual tumor involving the upper ureter and left kidney and a retroperitoneal lymph node dissection under a clinical diagnosis of recurrence of the testicular tumor.
  • Histologically, no viable cancer cells remained.
  • [MeSH-major] Kidney Pelvis / pathology. Neoplasm Recurrence, Local / pathology. Seminoma / pathology. Testicular Neoplasms / pathology. Ureteral Neoplasms / secondary
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chorionic Gonadotropin, beta Subunit, Human / blood. Cisplatin / administration & dosage. Etoposide / administration & dosage. Humans. Hydronephrosis / etiology. Male

  • Genetic Alliance. consumer health - Seminoma.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15509217.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin, beta Subunit, Human; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


20. Ricke J, Sehouli J, Hach C, Hänninen EL, Lichtenegger W, Felix R: Prospective evaluation of contrast-enhanced MRI in the depiction of peritoneal spread in primary or recurrent ovarian cancer. Eur Radiol; 2003 May;13(5):943-9
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective evaluation of contrast-enhanced MRI in the depiction of peritoneal spread in primary or recurrent ovarian cancer.
  • The purpose of this study was to assess the accuracy of MRI in the staging of intra-abdominal tumor seeding of ovarian carcinoma.
  • Fifty-seven patients with suspected primary or recurrent ovarian carcinoma were included in this study.
  • The MRI protocol included fat-saturated T1-weighted spin-echo (SE) sequences pre- and post i.v. application of gadopentetate dimeglumine.
  • The criteria for tumor manifestation was contrast enhancement of intra-abdominal soft tissue lesions or peritoneum.
  • Laparotomy and histopathology confirmed 251 abdominal tumor locations.
  • Sensitivity was high in lower pelvis locations (73-83%) except for ureter or bladder infiltration (40%).
  • Magnetic resonance imaging based on contrast-enhanced fat-saturated T1 SE sequences improves planning of cytoreduction preceding chemotherapy in advanced primary or relapsed ovarian carcinoma.
  • [MeSH-minor] Abdominal Neoplasms / diagnosis. Abdominal Neoplasms / secondary. Adult. Aged. Aged, 80 and over. False Positive Reactions. Female. Gastrointestinal Neoplasms / diagnosis. Gastrointestinal Neoplasms / secondary. Genital Neoplasms, Female / diagnosis. Genital Neoplasms, Female / secondary. Humans. Liver Neoplasms / diagnosis. Liver Neoplasms / secondary. Lymphatic Metastasis. Middle Aged. Neoplasm Recurrence, Local. Neoplasms, Second Primary. Pelvic Neoplasms / diagnosis. Pelvic Neoplasms / secondary. Predictive Value of Tests. Prospective Studies. Sensitivity and Specificity. Single-Blind Method. Women's Health

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12695813.001).
  • [ISSN] 0938-7994
  • [Journal-full-title] European radiology
  • [ISO-abbreviation] Eur Radiol
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


21. Bondavalli C, Dall'Oglio B, Schiavon L, Luciano M, Guatelli S, Parma P, Galletta V: [Complications of urinary diversion after radiotherapy]. Arch Ital Urol Androl; 2003 Mar;75(1):10-3
MedlinePlus Health Information. consumer health - After Surgery.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary radiation therapy may be recommended for patients with invasive bladder cancer, gynecological or prostatic cancer.
  • When complications occur or in case of malignant recurrence, urinary diversion may be the best chance to restore an acceptable quality of life.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12741338.001).
  • [ISSN] 1124-3562
  • [Journal-full-title] Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica
  • [ISO-abbreviation] Arch Ital Urol Androl
  • [Language] ITA
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 24
  •  go-up   go-down


22. Mouracade P: Re: Should patients with primary upper urinary tract cancer receive prophylactic intravesical chemotherapy after nephroureterectomy?: W. J. Wu, H. L. Ke, Y. H. Yang, C. C. Li, Y. H. Chou and C. H. Huang J Urol 2010; 183: 56-61. J Urol; 2010 Oct;184(4):1571
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Re: Should patients with primary upper urinary tract cancer receive prophylactic intravesical chemotherapy after nephroureterectomy?: W. J. Wu, H. L. Ke, Y. H. Yang, C. C. Li, Y. H. Chou and C. H. Huang J Urol 2010; 183: 56-61.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Kidney Neoplasms / prevention & control. Neoplasm Recurrence, Local / prevention & control. Neoplasms, Second Primary / prevention & control. Nephrectomy. Ureter / surgery. Ureteral Neoplasms / prevention & control. Urinary Bladder Neoplasms / prevention & control

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] J Urol. 2010 Jan;183(1):56-61 [19913833.001]
  • (PMID = 20728904.001).
  • [ISSN] 1527-3792
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down






Advertisement